What is the 13F Pro Quality Score for GDRX?

13F Pro ranks GoodRx Holdings, Inc. (GDRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GDRX's current score at https://13fpro.ai/research/GDRX (free sign-up required for the full ranking).

Where does 13F Pro source GDRX data?

All GoodRx Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. GoodRx Holdings, Inc. files with the SEC under CIK 1809519. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GDRX in?

GoodRx Holdings, Inc. (GDRX) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

How often is GDRX research updated on 13F Pro?

GDRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GoodRx Holdings, Inc.(GDRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1809519 GDRX stock profile & AI dashboard →

13F Pro Quality Score

52.5/100

Rank #1,339 of 2,879 stocksTOP 50%

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

43.1/100

Profitability

63.2/100

Balance Sheet

50.7/100

Earnings Quality

75.0/100

Free Cash Flow

76.2/100

Institutional Flow

16.3/100

Revenue Scale

45.1/100

Dilution Risk

17.3/100

GDRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GoodRx Holdings, Inc. (GDRX), a Technology sector company. 13F Pro's AI-powered ranking engine scores GDRX at 52.5/100 on a 32-signal composite quality model, placing it at rank #1,339 of 2,879 stocks — the top half of the AI-ranked universe. GDRX scores in the top quartile across free cash flow (76.2), earnings quality (75.0). Areas of concern include institutional flow (16.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), GoodRx Holdings, Inc. reports quarterly revenue of $194.0M, net income of $1.2M, an operating margin of 7.2%. Top institutional holders of GDRX by reported 13-F value include Francisco Partners Management,, AMERIPRISE FINANCIAL, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GDRX trades on the Nasdaq exchange and files with the SEC under CIK 1809519. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GDRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GoodRx Holdings, Inc. directly from SEC EDGAR. GoodRx Holdings, Inc.'s 13F Pro composite quality score has ranged between 40 and 57 since 2021, currently 52.5 — an improving long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about GoodRx Holdings, Inc.

Quirks, history, and lore behind GDRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. health-tech company · mid-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the range of $800 million, serving roughly 25 million monthly active consumers — yet it has never been consistently profitable.
3
The History
Founded around 2011, it was built on the insight that prescription drug prices in America are wildly inconsistent — and that showing patients a better price could be a business.
4
The Secret
It makes money not by selling drugs, but by collecting fees from pharmacies every time a customer uses one of its discount codes at the counter.
5
The Lore
Its co-founders include alumni of Facebook and Yelp, and it went public during the pandemic in 2020 — briefly becoming a darling of the telehealth boom.
6
The Giveaway
You've seen the TV commercials: pull up the app, show the pharmacist the card, and suddenly that $300 prescription costs $18 — no insurance required.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$194.0M

Net Income

Q1 2026

$1.2M

Free Cash Flow

Q1 2026

$10.7M

Operating Margin

Q1 2026

7.2%

ROIC

Q1 2026

1.3%

D/E Ratio

Q1 2026

0.78

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.6% YoY

$796.9MFY 2025

FY21 $745.4MFY23 $750.3MFY24 $792.3MFY25 $796.9M

Net Income

+85.4% YoY

$30.4MFY 2025

FY21 $-25.3MFY23 $-8.9MFY24 $16.4MFY25 $30.4M

Operating Income

+32.9% YoY

$87.5MFY 2025

FY21 $13.4MFY23 $-27.0MFY24 $65.8MFY25 $87.5M

EPS (Diluted)

+125.0% YoY

$0.09FY 2025

FY21 $-0.06FY23 $-0.02FY24 $0.04FY25 $0.09

Total Assets

+1.2% YoY

$1.40BFY 2025

FY21 $1.61BFY23 $1.59BFY24 $1.39BFY25 $1.40B

Total Debt

-1.0% YoY

$500.0MFY 2025

FY21 $681.1MFY23 $656.5MFY24 $505.0MFY25 $500.0M

Op. Cash Flow

-8.7% YoY

$167.9MFY 2025

FY21 $178.8MFY23 $138.3MFY24 $183.9MFY25 $167.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2018
Revenue	$796.9M +0.6%	$792.3M +5.6%	$750.3M +0.6%	$745.4M +92.0%	$388.2M +55.6%	$249.5M
Net Income	$30.4M +85.4%	$16.4M +284.9%	$-8.9M +64.9%	$-25.3M -138.3%	$66.0M +50.8%	$43.8M
Operating Income	$87.5M +32.9%	$65.8M +343.8%	$-27.0M -301.5%	$13.4M -90.4%	$139.7M +80.8%	$77.3M
EPS (Diluted)	$0.09 +125.0%	$0.04 +300.0%	$-0.02 +66.7%	$-0.06 -133.3%	$0.18 +50.0%	$0.12
Total Assets	$1.40B +1.2%	$1.39B -12.6%	$1.59B -1.2%	$1.61B +315.6%	$386.8M	—
Total Debt	$500.0M -1.0%	$505.0M -23.1%	$656.5M -3.6%	$681.1M +0.5%	$678.0M	—
Operating Cash Flow	$167.9M -8.7%	$183.9M +33.0%	$138.3M -22.6%	$178.8M +114.7%	$83.3M +84.0%	$45.3M

AI Insight: GDRX Ratio Trends

GDRX profitability deteriorated sharply in Q1 2026 with operating margin collapsing to 7.2% from 11.7% in Q4 2025.

• Operating margin fell from 11.7% in Q4 2025 to 7.2% in Q1 2026, continuing volatile quarterly swings.

• Net profit margin dropped to 0.6% in Q1 2026 from 2.8% in Q4 2025.

• ROIC declined to 5.1% in Q1 2026 from 8.1% in Q4 2025, near cycle lows.

• Debt-to-equity ratio remained stable around 0.78 in Q1 2026, down from 0.97 peak in Q2 2024.

⚠ Extreme quarterly volatility in margins suggests unstable business fundamentals or irregular expense timing.

⚠ ROA fell to just 0.2% in Q1 2026, indicating very poor asset utilization efficiency.

Get alerted when GDRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GoodRx Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GDRX

Francisco Partners Management, LP
$117.8M60,078,184 sh
AMERIPRISE FINANCIAL INC
$8.7M4,455,760 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.4M4,261,516 sh
Silver Lake Group, L.L.C.
$6.9M3,532,276 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$6.6M3,362,864 sh
RENAISSANCE TECHNOLOGIES LLC
$6.4M3,259,738 sh
Petrus Trust Company, LTA
$6.1M3,098,559 sh
DIMENSIONAL FUND ADVISORS LP
$4.8M2,451,141 sh
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
$4.1M2,105,502 sh
BlackRock, Inc.
$3.6M1,861,591 sh

Fund	Value	Shares
Francisco Partners Management, LP	$117.8M	60,078,184
AMERIPRISE FINANCIAL INC	$8.7M	4,455,760
VANGUARD CAPITAL MANAGEMENT LLC	$8.4M	4,261,516
Silver Lake Group, L.L.C.	$6.9M	3,532,276
VANGUARD PORTFOLIO MANAGEMENT LLC	$6.6M	3,362,864
RENAISSANCE TECHNOLOGIES LLC	$6.4M	3,259,738
Petrus Trust Company, LTA	$6.1M	3,098,559
DIMENSIONAL FUND ADVISORS LP	$4.8M	2,451,141
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.	$4.1M	2,105,502
BlackRock, Inc.	$3.6M	1,861,591

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put GDRX on your watchlist

Track score changes the day GoodRx Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GDRX a good stock to buy?

13F Pro's AI-powered analysis of GoodRx Holdings, Inc. (GDRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GDRX are available on the GDRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GDRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GDRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GoodRx Holdings, Inc.'s investment landscape.